Platelet phenotyping by immunofluorescence microscopy on the blood smear in subjects with myeloprolipherative disorders

Platelet phenotyping by immunofluorescence microscopy on the blood smear in subjects with myeloprolipherative disorders - MPN-IF-Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032588

Enrollment

200

Registered

2023-09-19

Start date

2021-01-07

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D47.1

Interventions

Group 1: During the first phase (detection-phase), the platelet phenotype of patients belonging to the detection cohort (n=140) had been assessed by immunofluorescence microscopy on the blood smears b

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Ensured diagnosis of clonal, myeloid disorder (CHIP, CCUS, ICUS, MDS, MPN, MDS-MPN-Overlap, CML or MDS/AML according to WHO), as well as healthy controls.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
To identify possible correlations between platelet phenotype determined by light- and immunofluorescence microscopy and clinical or genetic characteristics of MPN patients that may be diagnostically and prognostically relevant.	—

Secondary

Measure	Time frame
To distinguish MPN patients from healthy controls, based on the found correlations described in the primary endpoint.	—

Countries

Germany

Contacts

Public ContactAndreas Greinacher

Institut für Transfusionsmedizin, Universitätsmedizin Greifswald

andreas.greinacher@med.uni-greifswald.de+4903834865479

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026